Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Sunshine Biopharma Inc. Warrant (SBFMW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: SBFMW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -100% | Avg. Invested days 18 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.96 | 52 Weeks Range 0.05 - 0.98 | Updated Date 05/25/2025 |
52 Weeks Range 0.05 - 0.98 | Updated Date 05/25/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.21 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -13.88% | Operating Margin (TTM) -14.56% |
Management Effectiveness
Return on Assets (TTM) -11.78% | Return on Equity (TTM) -21.17% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 4553895 |
Shares Outstanding - | Shares Floating 4553895 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Sunshine Biopharma Inc. Warrant
Company Overview
History and Background
Sunshine Biopharma Inc. is focused on the research, development, and commercialization of oncology and antiviral drugs. The warrants represent the right to purchase shares of the company's common stock at a specified price.
Core Business Areas
- Oncology: Development of anti-cancer drugs, including preclinical and clinical trials.
- Antiviral: Research and development of antiviral therapies to combat viral infections.
Leadership and Structure
Key personnel include the CEO and other executive officers. Organizational structure typically involves departments for research and development, clinical trials, and regulatory affairs.
Top Products and Market Share
Key Offerings
- Adva-27a: A proprietary molecule being developed as a potential treatment for various cancers. Market share data is not yet available, as the product is still in development. Competitors include major pharmaceutical companies such as Pfizer, Novartis and Bristol Myers Squibb, etc.
- mRNA Drug Molecules: Developing mRNA molecules for various oncology applications. Market share data is not yet available, as the product is still in development. Competitors: Moderna, BioNTech.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, lengthy regulatory approval processes, and significant market potential for successful drugs.
Positioning
Sunshine Biopharma Inc. is positioned as a development-stage company focusing on novel therapies in the oncology and antiviral fields. Its competitive advantage lies in its proprietary drug candidates.
Total Addressable Market (TAM)
The global oncology and antiviral drug markets are estimated to be worth hundreds of billions of dollars. Sunshine Biopharma is positioned to capture a small fraction of this market with successful products.
Upturn SWOT Analysis
Strengths
- Proprietary drug candidates
- Focus on high-growth therapeutic areas
- Experienced management team
Weaknesses
- Limited financial resources
- Reliance on successful clinical trials
- Early stage of development
Opportunities
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results
- Expansion into new therapeutic areas
Threats
- Regulatory hurdles
- Competition from established players
- Failure of clinical trials
Competitors and Market Share
Key Competitors
- PFE
- MRNA
- NVS
- BMY
Competitive Landscape
Sunshine Biopharma Inc. faces intense competition from established pharmaceutical companies with greater resources and experience. Its advantages lie in its novel drug candidates and focused therapeutic areas.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is tied to the company's progress in developing and commercializing its drug candidates.
Future Projections: Future growth depends on successful clinical trials, regulatory approvals, and commercialization efforts.
Recent Initiatives: Recent initiatives include advancing clinical trials, seeking partnerships, and exploring new therapeutic applications.
Summary
Sunshine Biopharma Inc. is a development-stage biopharmaceutical company with promising drug candidates but faces significant risks and competition. Successful clinical trials and strategic partnerships are critical for its future growth. Its warrants represent a speculative investment tied to the company's long-term potential. Cashflow is a concern.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. The data provided may not be complete or accurate. Investing in biopharmaceutical companies is highly speculative and involves significant risks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sunshine Biopharma Inc. Warrant
Exchange NASDAQ | Headquaters Fort Lauderdale, FL, United States | ||
IPO Launch date 2022-02-15 | Chairman, President & CEO Dr. Steve N. Slilaty Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 52 | Website https://sunshinebiopharma.com |
Full time employees 52 | Website https://sunshinebiopharma.com | ||
Sunshine Biopharma, Inc. operates as a pharmaceutical company that focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates through Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products segments. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine The company is based in Fort Lauderdale, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.